In vitro flow rate dependency of delivered dose and fine particle dose of Salmeterol/Fluticasone Propionate Easyhaler® and Seretide Diskus® with patient flow rates collected in a randomized controlled trial.

Publikationer | 2023-08-30

Study summary:

In vitro flow rate dependency of delivered dose and fine particle dose of Salmeterol/Fluticasone Propionate Easyhaler^® and Seretide Diskus^® with patient flow rates collected in a randomized controlled trial.

Jõgi et al. 2018. JAMP

In vitro flow rate dependence of delivered dose (DD) and fine particle dose (FPD) of Salmeterol/Fluticasone Propionate Easyhaler^® and Seretide Diskus^® was assessed across a range of clinically relevant flow rates in patients with asthma or COPD.
The lung deposition characteristics of Salmeterol/Fluticasone Propionate Easyhaler^® – flow rate dependence of DD and FPD – were similar to the originator product Seretide Diskus^®.
The inhalation flow rates did not substantially influence the dosing characteristics of Salmeterol/Fluticasone Propionate Easyhaler^®.

The clinical effectiveness of dry powder inhalers (DPI) is influenced by various factors, such as inhalation flow generated by the patient, resistance to air flow within the device, accuracy and consistency of dosing in various patient inhalation flows, and dose linearity at different dose strengths. The aim of this study was to assess the in vitro flow rate dependence of DD and FPD of Salmeterol/Fluticasone Propionate Easyhaler^® and to compare it to the originator product Seretide Diskus^®.

Inhalation flow rates (L/min) of 164 patients with asthma (children, adolescents, adults, and elderly) and 52 patients with COPD were measured by spirometry as peak inspiratory flow (PIF). In the subsequent in vitro study, a low (10^th percentile), median (50^th percentile), and high (90^th percentile) of collected flow rates were used to evaluate the flow rate dependence of DD and FPD. The flow rate dependencies were determined as relative to median flow (percentage) at product strengths of 50/250 µg and 50/500 µg/dose. In total, 72 inhalers from two batches of Salmeterol/Fluticasone Propionate Easyhaler and 84 inhalers from two batches of Seretide Diskus were used in the in vitro study.

The results demonstrated that almost all adult and adolescent patients with asthma reached a PIF rate of 30 L/min or higher (Figure 1). Further evaluation of the collected flow rates showed that the flow rate dependence of DD (Figure 2) and FPD (Figure 3), across the 10^th, 50^th, and 90^th percentile air flow rates of Salmeterol/Fluticasone Propionate Easyhaler, were similar to Seretide Diskus. In addition, DD and FPD were largely independent of flow rate for both dose strengths, indicating that dosing characteristics were not significantly influenced by inhalation flow rates.

Figure 1. Individual PIF rates in patients with asthma or COPD for Salmeterol/Fluticasone Easyhaler.

Figure 1. Individual PIF rates in patients with asthma or COPD for Salmeterol/Fluticasone Propionate Easyhaler. N = 216. Note: Children (4-11 years of age) are not included in the indication for Salmeterol/Fluticasone Propionate Easyhaler.*

Figure 2. Flow rate dependence of delivered dose (DD) of Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Figure 2. Flow rate dependence of delivered dose (DD) of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus. 10^th, 50^th, and 90^th percentile air flow rates for Salmeterol/Fluticasone Propionate Easyhaler were 46, 68, and 85 L/min, and for Seretide Diskus 44, 71, and 96 L/min.

Figure 3. Flow rate dependence of fine particle dose (FPD) of Salmeterol/Fluticasone Easyhaler and Seretide Diskus.

Figure 3. Flow rate dependence of fine particle dose (FPD) of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus. 10^th, 50^th, and 90^th percentile air flow rates for Salmeterol/Fluticasone Propionate Easyhaler were 46, 68, and 85 L/min, and for Seretide Diskus 44, 71, and 96 L/min.

This study demonstrated overall similar in vitro flow rate dependence of DD and FPD between Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus, using clinically relevant flow rates collected from the patients with asthma and COPD. The results suggest that the lung deposition characteristics are similar between both products, and that the inhalation flow rate does not substantially influence the dosing characteristics of Salmeterol/Fluticasone Propionate Easyhaler.

Jõgi R, Lähelmä S, Vahteristo M, Happonen A, Haikarainen J. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial. J Aerosol Med Pulm Drug Deliv. 2018 Oct 9. doi:10.1089/jamp.2018.1463

*Salmeterol/Fluticasone Propionate Easyhaler^®50/250 and 50/500 µg. SmPC. Orion Pharma

Minimiinformation

Salflumix Easyhaler® (salmeterol/flutikasonpropionat) [Rx] F. Astma: Inhalationspulver i styrkorna 50/250 mikrogram och 50/500 mikrogram. För regelbunden behandling av bronkialastma hos vuxna och ungdomar 12 år och äldre, när kombinationsbehandling (långverkande ß2-agonist och inhalationssteroid) är lämplig för: patienter som inte uppnår adekvat symtomkontroll med inhalationssteroid och ’vid behovs’ medicinering med inhalerad kortverkande ß2-agonist eller patienter som redan har adekvat symtomkontroll med inhalationssteroid och långverkande ß2-agonist. KOL: Inhalationspulver i styrkan 50/500 mikrogram. Salflumix Easyhaler är indicerad för symtomatisk behandling av patienter från 18 år med KOL med ett FEV1 <60% av beräknat normalvärde (före bronkdilaterare) och med upprepade försämringsepisoder i sjukdomshistorien samt betydande symtom trots regelbunden behandling med bronkdilaterare. Senaste översyn av produktresuméer: 2022-12-08. För priser och ytterligare information se www.fass.se.

Var den här artikeln användbar för dig?

ORIONPHARMA.SE